CAS 1326244-10-3: Tildrakizumab

Description:Tildrakizumab is a monoclonal antibody that specifically targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. It is primarily used in the treatment of moderate to severe plaque psoriasis. As a humanized IgG1κ antibody, Tildrakizumab works by inhibiting the interaction between IL-23 and its receptor, thereby reducing the inflammatory response associated with autoimmune conditions. The molecular structure of Tildrakizumab allows for high specificity and affinity for IL-23, contributing to its therapeutic efficacy. It is administered via subcutaneous injection and has a favorable pharmacokinetic profile, allowing for dosing at intervals that can range from every few weeks to several months, depending on the treatment regimen. Common side effects may include injection site reactions, upper respiratory infections, and headaches, but it is generally well-tolerated. As with other biologics, monitoring for potential infections and other immune-related effects is essential during treatment. Overall, Tildrakizumab represents a targeted approach in the management of psoriasis, reflecting advancements in biologic therapies.

Formula:Unspecified

Synonyms:
Immunoglobulin G1, anti-(human interleukin 23) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer
Tildrakizumab-asmn
Ilumya
Tildrakizumab
Ilumetri

Found 2 products.

Brand	Product data	Purity	Price range	Estimated delivery
	Tildrakizumab REF: TM-T76784CAS: 1326244-10-3	> 95%	311.00 €~1,311.00 €	Wed 16 Apr 25
	Tildrakizumab REF: 3D-CLA1317CAS: 1326244-10-3	- - -	To inquire	Mon 28 Apr 25